bluebird bio, Inc. BLUE
Set alert
At close · Jun 2
52-week range unavailable
- YTD
- -40.41%
- 1 year
- -72.25%
- Open
- 4.97
- Prev close
- 4.97
- Mkt cap
- 75.74M
- Vol
- 1.25M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.97
- High
- 4.97
- Forward P/E
- -11.98
- Beta
- 0.80
- Short ratio
- 9.53
- Inst. own
- 43.69%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 8.54
- 200-d avg
- 16.13
- 1y target
- 37.71
2Y chart
Events in this range
- Aug 8, 2023Earnings: -13.4; estimate -14.4; surprise 6.94%
- Nov 7, 2023Earnings: -13.2; estimate -13.8; surprise 4.35%
- Aug 15, 2024Rating: B of A Securities · Buy → Buy
- Sep 13, 2024Earnings: -15.6; estimate 0; surprise —%
- Sep 16, 2024Rating: Cantor Fitzgerald · — → Neutral
- Sep 25, 2024Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Nov 14, 2024Earnings: -6.2; estimate -7.6; surprise 18.42%
- Nov 15, 2024Rating: Barclays · Overweight → Overweight
- Nov 15, 2024Downgrade: B of A Securities · Buy → Neutral
- Nov 15, 2024Rating: RBC Capital · Sector Perform → Sector Perform
- Dec 13, 2024Split: 1 for 20
Signals (89)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | May 14, 2025 | 1 year ago |
| MACD: Buy Signal | May 14, 2025 | 1 year ago |
| RSI: Oversold | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 17, 2025 | 1 year ago |
| SMA: Bearish | Apr 14, 2025 | 1 year ago |
| SMA: Bullish | Apr 11, 2025 | 1 year ago |
| RSI: Oversold | Mar 13, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 21, 2025 | 1 year ago |
| RSI: Oversold | Feb 21, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 14, 2025 | 1 year ago |
| SMA: Bearish | Jan 22, 2025 | 1 year ago |
| SMA: Bullish | Jan 15, 2025 | 1 year ago |
| SMA: Bearish | Jan 14, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
| SMA: Bullish | Jan 2, 2025 | 1 year ago |
| SMA: Bearish | Dec 30, 2024 | 1 year ago |
| SMA: Bullish | Dec 26, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 26, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 24, 2024 | 1 year ago |
Newest 20 of 89.
Key statistics
- Market cap
- 75.74M
- Enterprise value
- 321.89M
- Trailing P/E
- 0.00
- Forward P/E
- -11.98
- PEG ratio
- 0.00
- Price / sales
- 1.38
- Price / book
- 7.72
- EPS (TTM)
- -36.00
- Beta
- 0.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 54.90M
- Revenue growth
- 133.70%
- Free cash flow
- -163.92M
- Total cash
- 144.07M
- Total debt
- 395.64M
- Return on equity
- -186.70%
- Shares outstanding
- 9.72M
- Short % of float
- 26.66%
- 50-day average
- 8.54
- 200-day average
- 16.13
Analyst view
Consensus: hold
- Target (low)
- 10.00
- Target (mean)
- 37.71
- Target (high)
- 80.00
- Strong buy1
- Buy1
- Hold6
- Sell0
- Strong sell2
Next earnings
Consensus EPS estimate -5.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -7.60 | -6.20 | +1.40 | +18.42% |
| Sep 13, 2024 | Dec 1, 2023 | 0.00 | -15.60 | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -13.80 | -13.20 | +0.60 | +4.35% |
| Aug 8, 2023 | Jun 1, 2023 | -14.40 | -13.40 | +1.00 | +6.94% |
| May 9, 2023 | Mar 1, 2023 | -10.80 | 4.20 | +15.00 | +138.89% |
| Mar 29, 2023 | Dec 1, 2022 | -9.00 | 7.60 | +16.60 | +184.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| Nov 15, 2024 | B of A Securities | down | Buy | Neutral |
| Nov 15, 2024 | Barclays | main | Overweight | Overweight |
| Sep 25, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Sep 16, 2024 | Cantor Fitzgerald | reit | — | Neutral |
| Aug 15, 2024 | B of A Securities | main | Buy | Buy |
About bluebird bio, Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bluebirdbio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on BLUE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGWUNOBI JOHN O | Director | Stock Award(Grant) | Nov 5, 2024 | 51,364 |
| COLVIN RICHARD A | Officer | Sale | Dec 9, 2024 | 165,544 |
| JONES-BURTON CHARLOTTE M.D. | Director | Stock Award(Grant) | Nov 5, 2024 | 43,462 |
| LEIDERMAN ELISABETH M.D. | Director | Stock Award(Grant) | Nov 5, 2024 | 47,156 |
| LESCHLY NICK | Director | Stock Award(Grant) | Nov 5, 2024 | 484,538 |
| OBENSHAIN ANDREW | Chief Executive Officer | Sale | Dec 9, 2024 | 374,247 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 0.40% | 772,190 | 6.02M | Sep 29, 2024 |
| Vanguard Group Inc | 0.27% | 523,700 | 4.08M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.12% | 234,152 | 1.82M | Sep 29, 2024 |
| State Street Corporation | 0.10% | 192,096 | 1.50M | Sep 29, 2024 |
| FMR, LLC | 0.06% | 124,098 | 966.72K | Sep 29, 2024 |
| Avidity Partners Management, LP | 0.04% | 81,557 | 635.33K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.15% | 293,123 | 2.28M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.13% | 250,270 | 1.95M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.08% | 159,570 | 1.24M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.05% | 98,622 | 768.26K | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.05% | 92,047 | 717.05K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.03% | 54,344 | 423.34K | Oct 30, 2024 |